Elacestrant vs Vepdegestrant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Elacestrant
Marketed by Stemline Therapeutics, Inc. and partners
NCT03778931 · Phase 3 · completed
This was a large randomized trial comparing elacestrant with active standard-of-care treatment, but it was open-label rather than double-blind. The primary progression-free survival endpoints, assessed by blinded imaging review, were statistically significantly better with elacestrant in both ESR1-mutant and all participants, but the lack of participant and investigator blinding limits the strength of the evidence.
Next expected readout: November 2026 · NCT06691035 (registry estimate)
Reported efficacy
Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)); Progression-free Survival in All Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14) (met)
Result source: NCT03778931
Vepdegestrant · Veppanu
Marketed by Rigel Pharmaceuticals and partners
NCT05654623 · Phase 3 · active, not recruiting
Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.
Next expected readout: December 2026 · NCT05909397 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)
Result source: NCT05654623
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Elacestrant | Vepdegestrant |
|---|---|---|
| PFS, median | 3.8 vs 1.9vs Standard of Care (SoC)NCT037789311 other result
| 3.7 vs 3.6vs FulvestrantNCT056546231 other result
|
| OS, median | —Trial running · NCT06382948 | —Trial running · NCT05909397 |
| ORR | —Trial running · NCT06382948 | 10.9% vs 3.6%vs FulvestrantNCT05654623 |
| Clinical benefit rate | —Trial running · NCT06382948 | 34.3% vs 28.7%vs FulvestrantNCT05654623 |
PFS, median
- Elacestrant
- 3.8 vs 1.9vs Standard of Care (SoC)NCT03778931
1 other result
- 2.8 vs 1.9 NCT03778931
- Vepdegestrant
- 3.7 vs 3.6vs FulvestrantNCT05654623
1 other result
- 5 vs 2.1 NCT05654623
OS, median
- Elacestrant
- —Trial running · NCT06382948
- Vepdegestrant
- —Trial running · NCT05909397
ORR
- Elacestrant
- —Trial running · NCT06382948
- Vepdegestrant
- 10.9% vs 3.6%vs FulvestrantNCT05654623
Clinical benefit rate
- Elacestrant
- —Trial running · NCT06382948
- Vepdegestrant
- 34.3% vs 28.7%vs FulvestrantNCT05654623
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Elacestrant: 3 of 4 rows · Vepdegestrant: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Elacestrant | Vepdegestrant |
|---|---|---|
| Dropout rate | 36.4% NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 7.8%a NCT05549505 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | — NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | —a NCT05549505 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 12.2% NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 4%a NCT05549505 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | nausea 35% fatigue 19% vomiting 19% NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | a hot flush 24.8% asthenia 20.8% constipation 15.8% NCT05549505 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Elacestrant
show 1 more result
Vepdegestrant
Breast Cancer
Shared mechanism: Estrogen receptor · full Breast Cancer pipeline
Elacestrant
Marketed by Stemline Therapeutics, Inc. and partners
NCT03778931 · Phase 3 · completed
This was a large randomized trial comparing elacestrant with active standard-of-care treatment, but it was open-label rather than double-blind. The primary progression-free survival endpoints, assessed by blinded imaging review, were statistically significantly better with elacestrant in both ESR1-mutant and all participants, but the lack of participant and investigator blinding limits the strength of the evidence.
Next expected readout: November 2026 · NCT06691035 (registry estimate)
Reported efficacy
Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)); Progression-free Survival in All Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14) (met)
Result source: NCT03778931
Vepdegestrant · Veppanu
Marketed by Rigel Pharmaceuticals and partners
NCT05654623 · Phase 3 · active, not recruiting
Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.
Next expected readout: December 2026 · NCT05909397 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)
Result source: NCT05654623
Results for Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Elacestrant: 4 of 5 rows · Vepdegestrant: 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Elacestrant | Vepdegestrant |
|---|---|---|
| PFS time to event · months | 3.78 vs 1.87 Standard of Care (SoC) monthsa,b NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose2.79 vs 1.91 Standard of Care (SoC) months NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 3.7 vs 3.6 Fulvestrant monthsa,b NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose5 vs 2.1 Fulvestrant months NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Dropout rate | 36.4% NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 7.8%c NCT05549505 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | — NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | —c NCT05549505 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 12.2% NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 4%c NCT05549505 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | nausea 35% fatigue 19% vomiting 19% NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | c hot flush 24.8% asthenia 20.8% constipation 15.8% NCT05549505 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bThe assessment timepoint is not available for both results.
- cPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Elacestrant
show 1 more result
Vepdegestrant
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elacestrant's landscape · Vepdegestrant's landscape